LSI Stock Chart & Stats
€0.10
€0.00(0.00%)
At close: 4:00 PM EST
€0.10
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.06 - €0.11
Previous CloseN/A
Volume0.00
Average Volume (3M)678.00
Market Cap
€614.07M
Enterprise Value€12.46B
Total Cash (Recent Filing)€603.07M
Total Debt (Recent Filing)€6.62B
Price to Earnings (P/E)―
Beta0.93
Next Earnings
Aug 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding9,611,072,000
10 Day Avg. Volume2,035
30 Day Avg. Volume678
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)2.09
Price to Sales (P/S)1.46
P/FCF Ratio-28.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Diversified Life-sciences Business MixA multi-segment business model across health, agriculture and environmental services spreads demand and regulatory risk, enabling more stable aggregate revenue streams. Diversification supports resilience to single-market shocks and allows redeploying capital into stronger segments over months.
Meaningful Equity Capital BaseA substantive equity base provides a capital cushion to absorb near-term losses and fund operations or strategic R&D. This balance-sheet depth increases the company's ability to withstand funding stress and pursue investment or restructuring without immediate dilution.
Historic Operating Cash Generation RecordPrior multi-year positive operating cash flow shows the business model can generate internal funding once margins stabilize. That track record suggests management can restore cash conversion through cost or mix improvements, aiding medium-term recovery of funding flexibility.
Bears Say
Sharp Margin Compression And Recent LossesA large, recent drop in gross margin and shift to operating losses materially weakens intrinsic profitability and cash conversion. Sustained margin pressure undermines reinvestment capacity and competitive position until structural cost, pricing, or product-mix fixes are implemented.
Large Negative Free Cash Flow In 2025A sizable FCF outflow reduces internal funding for capex, R&D and working capital, increasing reliance on external financing. Persistent negative FCF elevates refinancing and liquidity risk and limits ability to invest in growth or absorb further operational setbacks.
Elevated And Rising LeverageHigh and rising leverage constrains strategic flexibility, increases interest and covenant risk, and magnifies earnings volatility. Until leverage is reduced, the company faces limited capacity to pursue acquisitions or growth investments and greater vulnerability to downturns.
CK Life Sciences International (Holdings), Inc. News
LSI FAQ
What was CK Life Sciences International (Holdings), Inc.’s price range in the past 12 months?
CK Life Sciences International (Holdings), Inc. lowest stock price was €0.06 and its highest was €0.11 in the past 12 months.
What is CK Life Sciences International (Holdings), Inc.’s market cap?
CK Life Sciences International (Holdings), Inc.’s market cap is €614.07M.
When is CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date?
CK Life Sciences International (Holdings), Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 16 days.
How were CK Life Sciences International (Holdings), Inc.’s earnings last quarter?
CK Life Sciences International (Holdings), Inc. released its earnings results on Mar 17, 2026. The company reported >-€0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-€0.001.
Is CK Life Sciences International (Holdings), Inc. overvalued?
According to Wall Street analysts CK Life Sciences International (Holdings), Inc.’s price is currently Overvalued.
Does CK Life Sciences International (Holdings), Inc. pay dividends?
CK Life Sciences International (Holdings), Inc. does not currently pay dividends.
What is CK Life Sciences International (Holdings), Inc.’s EPS estimate?
CK Life Sciences International (Holdings), Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CK Life Sciences International (Holdings), Inc. have?
CK Life Sciences International (Holdings), Inc. has 9,611,072,000 shares outstanding.
What happened to CK Life Sciences International (Holdings), Inc.’s price movement after its last earnings report?
CK Life Sciences International (Holdings), Inc. reported an EPS of >-€0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.149%.
Which hedge fund is a major shareholder of CK Life Sciences International (Holdings), Inc.?
Currently, no hedge funds are holding shares in DE:LSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CK Life Sciences International (Holdings), Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
107.40%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.71%
Trailing 12-Months
Company Description
CK Life Sciences International (Holdings), Inc.
CK Life Sciences International (Holdings), Inc. operates as an investment company, which engages in the business of research and development, manufacturing, commercialization, marketing and selling of products and assets in nutraceuticals, pharmaceuticals and agriculture related business. It operates through the following segments: Agriculture-Related and Health. The company was founded on August 10, 2001 and is headquartered in Hong Kong.
Technical Analysis
Sino Biopharmaceutical
―
Ascletis Pharma, Inc.
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Simcere Pharmaceutical Group Limited
―
Shanghai Henlius Biotech, Inc. Class H
―